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Abstract
Purpose To evaluate pregnancy rates, time to pregnancy (TTP) and obstetric outcomes in female childhood cancer survivors 
(CCSs) and to identify specific diagnosis- and treatment-related factors associated with these outcomes.
Methods The study is part of the DCOG LATER-VEVO study, a nationwide multicenter cohort study evaluating fertility 
among long-term Dutch female CCSs. Data were collected by questionnaire. The current study included 1095 CCSs and 812 
controls, consisting of sisters of CCSs and a random sample of women from the general population.
Results Among the subgroup of women who ever had the desire to become pregnant, the chance of becoming pregnant 
was significantly lower for CCSs than controls (OR 0.5, 95%CI 0.4–0.8). Moreover, TTP was 1.1 times longer for CCSs 
compared to controls (p = 0.09) and was significantly longer in survivors of CNS and renal tumours. Overall, no differences 
were found between CCSs and controls regarding the probability of ever having had a miscarriage, still birth, or induced 
abortion. However, CCSs had a significantly increased risk of delivering preterm (OR 2.2, 95%CI 1.3–3.7) and delivering 
via caesarean section (OR 1.8, 95%CI 1.2–2.6). Treatment with lower abdominal/pelvic radiotherapy was strongly associated 
with several adverse obstetric outcomes.
Conclusion CCSs are less likely to have ever been pregnant. Among those who do become pregnant, certain subgroups of 
CCSs are at increased risk of longer TTP. Moreover, as pregnant CCSs, especially those treated with lower abdominal/pelvic 
radiotherapy, are more likely to develop various adverse obstetric outcomes, appropriate obstetric care is highly advocated.
Keywords Childhood cancer survivors · Pregnancy rates · Time to pregnancy · Obstetric outcomes
Introduction
Increased survival rates for childhood cancer have resulted 
in a growing population of childhood cancer survivors 
(CCSs) (Gatta et al. 2014). However, chemo- and radiother-
apy administered during childhood may compromise female 
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reproductive function resulting in infertility, subfertility, or 
a premature menopause due to a depletion of the ovarian 
follicle pool (Green et al. 2002, 2009a; Chemaitilly et al. 
2006; Sklar et al. 2006; van den Berg 2018). This may put 
CCSs at increased risk of a longer time to pregnancy (TTP) 
as seen in ageing women.
Pregnancy or live birth rates have consistently shown to 
be reduced among female CCSs, particularly after hypo-
thalamic-pituitary or pelvic radiotherapy and exposure to 
certain alkylating agents (Green et al. 2009b; Chow et al. 
2016; Anderson et al. 2018; Magelssen et al. 2008; Armuand 
et al. 2017; Madanat et al. 2008). However, marital status 
or the actual desire to conceive, factors known to be inde-
pendently associated with pregnancy rates, were not always 
taken into account. In addition, time to first pregnancy was 
found to be significantly longer in CCSs compared to sib-
lings, particularly after abdominal radiotherapy, but TTP 
for subsequent pregnancies was not evaluated (Green et al. 
2009b). As such, the impact of a possible treatment-related 
reduced ovarian reserve on TTP for subsequent pregnancies 
remains unknown.
Female CCSs considering pregnancy also have signifi-
cant concerns about treatment-related adverse pregnancy 
outcomes (Schover et al. 1999a, b). Following pelvic or 
abdominal radiotherapy women are indeed at increased risk 
of a miscarriage (Green et al. 2002; Reulen et al. 2009; Reu-
len et al. 2009; Chiarelli et al. 2000; Winther et al. 2008), 
preterm delivery, or delivering low-birthweight offspring 
(Green et al. 2002; Signorello et al. 2006). After cranial radi-
otherapy, however, conflicting results have been described 
(Green et al. 2002; Reulen et al. 2009; Winther et al. 2008), 
whereas chemotherapy has not been associated with adverse 
obstetric outcomes (Green et al. 2002; Reulen et al. 2009; 
Chiarelli et al. 2000; Signorello et al. 2006). These stud-
ies predominantly evaluated pregnancy outcomes related to 
first pregnancies only. Therefore, results may underestimate 
the actual risk of adverse pregnancy outcomes following 
childhood cancer treatment. Moreover, conflicting results 
have been described regarding the risk of a caesarean section 
among female CCSs (Reulen et al. 2017; van der Kooi et al. 
2018; Lie Fong et al. 2010).
So far, the effect of specific diagnosis- and treatment-
related factors on pregnancy rates in those who pursued a 
pregnancy, as well as on TTP and adverse obstetric outcomes 
among female CCSs remain largely unknown. In order to 
adequately counsel survivors regarding family planning and 
possible obstetric risks, identifying those at increased risk 
is warranted so that this information can feed into clinical 
guidelines for patient care. Therefore, the aim of the current 
study was to evaluate pregnancy rates, TTP and obstetric 
outcomes for all pregnancies in female CCSs compared to 
controls, and to investigate diagnosis- and treatment-related 
factors associated with these outcomes.
Methods
Study population
This study was conducted as part of the DCOG LATER-
VEVO study, a nationwide, multi-center retrospective cohort 
study among Dutch female CCSs aiming to evaluate the 
effects of childhood cancer treatment on fertility. The study 
design and data collection methods have been described pre-
viously (Overbeek et al. 2012). In short, the study popula-
tion consisted of adult women, treated for cancer before the 
age of 18 years between 1963 and 2002 who survived for 
at least five years after diagnosis (n = 2237). Sisters from 
participating CCSs and women from the general popula-
tion were included as control subjects (further referred to as 
controls) (van den Berg et al. 2014). All controls had never 
been diagnosed with cancer, were able to read and speak 
Dutch, and were also of adult age at time of study inclusion.
Data collection and outcomes
Data were collected by a questionnaire (de Boer et al. 2005) 
which addressed, among other items, socio-demographic 
characteristics, reproductive history, and lifestyle factors. 
Data included the number of pregnancies, time to each preg-
nancy (number of months of unprotected sexual intercourse 
until pregnancy), duration and outcome of each pregnancy 
(live birth, still birth, miscarriage, or induced abortion), 
birth weight, and mode of delivery (caesarean section yes/
no). Unsuccessful pregnancies ending before gestational 
week 20 were considered a miscarriage and from gestational 
week 20 onwards a stillbirth. A live birth before gestational 
week 37 was considered a preterm delivery. In addition, an 
infant was defined as small for gestational age (SGA) if the 
reported birthweight was below the 10th percentile of Dutch 
reference curves for birthweight by gestational age (Visser 
et al. 2009). Detailed data on cancer diagnosis and treatment 
were collected from original medical files.
Statistical analyses
Differences between socio-demographic characteristics 
of survivors and controls were analyzed using Chi-square 
tests, Student t-tests, or Mann–Whitney U tests, where 
appropriate.
Pregnancy rates and TTP were evaluated within the 
subgroup of participants who ever pursued a pregnancy. 
As such, virgins, as well as women who had never tried 
to become pregnant in the past, were excluded from these 
analyses. Also, women who ever unintentionally became 
pregnant, and reported that this pregnancy was terminated 
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by means of an induced abortion, were not included in 
order to avoid bias. All pregnancies, i.e. spontaneous con-
ceptions and conceptions by fertility treatment (7% and 5% 
of all pregnancies in CCSs and controls, respectively) were 
included in the analyses. Obstetric outcomes were evaluated 
not only in the group of women who ever pursued preg-
nancy but in the total group of participating women and all 
pregnancies were included with the exception of twin gesta-
tions (2% and 1% of all pregnancies of CCSs and controls, 
respectively) and on-going pregnancies (5% and 3% of all 
pregnancies for CCSs and controls, respectively).
Multivariable logistic regression analyses were used to 
calculate odds ratios (ORs) with 95% confidence intervals 
(CIs) for ever having been pregnant (yes/no). These analyses 
were adjusted for age and educational level at time of study.
Differences in TTP and obstetric outcomes between CCSs 
and controls were evaluated by multivariable analyses using 
Generalized Estimating Equations (GEE) models to account 
for potential correlations between pregnancies in the same 
woman. TTP was evaluated by calculating ratios with 95% 
CIs, as a measure of the change in TTP (in months) for sur-
vivors compared to controls. Overall differences between 
CCSs and controls regarding TTP were analyzed for first, 
second, and third pregnancies separately. Since the distri-
bution of data on TTP was highly skewed, data were log-
transformed prior to analyses. For the analysis concerning 
adverse obstetric outcomes, each outcome (i.e. still birth, 
miscarriage, or induced abortion) was evaluated relative to 
a live birth, meaning that only the positive outcome was 
included in the denominator. For pregnancies ending in a 
live birth, the following outcomes were dichotomized for 
each live birth: preterm delivery, delivery of a small for 
gestational age infant, and delivery by caesarean section. 
Analyses of TTP and obstetric outcomes were adjusted for 
maternal age at time of pregnancy and educational level, 
both predictors of TTP (Mutsaerts et al. 2012), preterm 
delivery, and SGA offspring (Ruiz et al. 2015) in the gen-
eral population.
Effects of diagnosis- and treatment-related factors on 
pregnancy rates, TTP, and adverse obstetric outcomes were 
assessed using five different multivariable models, with each 
model evaluating a specific factor: (1) type of diagnosis; (2) 
age group at diagnosis; (3) Cyclophosphamide Equivalent 
Dose (CED) score (Green et al. 2014); (4) radiotherapy body 
site; (5) having had a stem cell transplantation (SCT). In 
addition to these models, the effect of individual alkylating 
agents on pregnancy rates and TTP was evaluated. Analyses 
regarding the effect of radiotherapy body site on the study 
outcomes were additionally corrected for treatment with 
alkylating agents, whereas analyses concerning the effect 
of chemotherapy were corrected for treatment with gonado-
toxic radiotherapy (total body irradiation (TBI) and/or lower 
abdominal/pelvic irradiation) (van den Berg et al. 2018). 
For all analyses, the control group was used as the reference 
group. Only obstetric outcomes reported in ≥ 5 CCSs were 
included in analyses. When results showed a specific (age 
group at) diagnosis to be (borderline) significantly associ-
ated with one of the outcomes, additional analyses were per-
formed within this group (numbers permitting). For this pur-
pose, radiotherapy body sites and chemotherapy (alkylating 
agents yes/no) were added to the regression model, thereby 
further investigating which specific types of treatment seem 
to underlie this association.
A p-value of < 0.05 (two sided) was considered statisti-
cally significant. All analyses were conducted using Statisti-
cal package for Social Sciences (SPSS) version 22.0.
Ethical approval
Approval was obtained from the Medical Ethics Review 
Committees of the VU University Medical Center and writ-
ten informed consent was obtained from all participants.
Results
Of the 1749 CCSs and 1673 controls invited to participate 
in the study, 1095 (63%) and 812 (49%) completed the 
questionnaire (Table 1). Median [interquartile range (IQR)] 
age at time of study was 28.7 (12.5) and 32.7 (12.6) years 
for CCSs and controls, respectively (p < 0.001). Moreover, 
adjusted for age at study, CCSs were less likely to have a 
high educational level and to have ever been (living as) mar-
ried at time of study (both p < 0.001). Survivors’ median 
(IQR) age at diagnosis was 6.4 (8.4) years, and the majority 
was diagnosed with leukaemia (36%) or lymphoma (16%).
Pregnancy rates
In total, 482 out of 1095 (44%) survivors and 422 out of 812 
(52%) controls ever pursued a pregnancy. Among this sub-
group, 393 survivors (82%) and 383 (91%) controls reported 
at least one pregnancy at time of study (OR 0.5, 95%CI 
0.4–0.8). The mean [standard deviation (SD)] maternal age 
at first pregnancy was 27.4 (4.2) and 28.6 (4.7) years for 
CCSs and controls, respectively (p = 0.05). After adjustment 
for educational level, results showed a trend towards a lower 
maternal age at first pregnancy for CCSs compared to con-
trols (p = 0.08). Survivors of CNS or renal tumors, as well 
as those treated with high-dose cranial/spinal radiotherapy, 
medium and high-dose abdominal/pelvic radiotherapy, TBI, 
or stem cell transplantation, were significantly less likely to 
have ever been pregnant (Supplementary Table 1). None of 
the CED-score categories, nor any of the individual alkylat-
ing agents (yes/no), were significantly association with ever 
having been pregnant (data not shown).
 Journal of Cancer Research and Clinical Oncology
1 3
Table 1  Demographic 
characteristics of all 
participating childhood cancer 
survivors (CCSs) and controls
CCSs
(n = 1095)
Controls (n = 812) p-value
Age at time of study (years)
 Median (IQR) 28.5 (12.4) 32.7 (12.7) < 0.001
Educationa < 0.001b
 Low 93 (8.6) 24 (3.0)
 Medium 678 (62.4) 362 (44.9)
 High 315 (29.0) 420 (52.1)
Marital status < 0.001b
 Never married 308 (28.3) 146 (18.0)
 Ever married/living as married 782 (71.7) 664 (82.0)
BMI
 Median (IQR) 22.9 (5.6) 23.0 (4.8) 0.94
Age at cancer diagnosis (years)
 Median (IQR) 6.4 (8.4) –
 < 10 739 (67.5)
 ≥ 10 to < 13 164 (15.0)
 ≥ 13 192 (17.5)
Diagnosis
 Leukaemia 390 (35.6) –
 Lymphoma 177 (16.2) –
 CNS tumours 114 (10.4) –
 Neuroblastoma and other peripheral 
nervous cell tumours
69 (6.3) –
 Renal tumours 123 (11.2) –
 Bone tumours 69 (6.3) –
 Soft tissue sarcoma 75 (6.8) –
 Germ cell tumours 46 (4.2)
 Otherc 32 (2.9) –
Time since diagnosis (years)
 Median (IQR) 21.9 (12.0) –
CED-scored
 0 516 (48.5) –
 > 0 to ≤ 4000 mg/m2 233 (21.9) –
 > 4000 to ≤ 8000 mg/m2 142 (13.3) –
 > 8000 mg/m2 174 (16.3) –
Radiotherapy body site
 No RT 640 (59.0) –
 Cranial/spinal  RTe 232 (21.4) –
  Low dose (< 20 Gy) 48 (22.3)
  Medium dose (20–30 Gy) 86 (40.0)
  High dose (≥ 30 Gy) 81 (37.7)
 Lower abdominal/pelvic  RTf 88 (8.0) –
  Low dose (< 20 Gy) 36 (40.9)
  Medium dose (20–30 Gy) 20 (22.7)
  High dose (≥ 30 Gy) 32 (36.4)
 TBIg 33 (3.0) –
 Other RT 92 (8.5) –
Stem cell transplantation
 No 1039 (94.9) –
 Yes 46 (4.2)
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Time to pregnancy
Among those ever pregnant in the group of women who 
ever pursue a pregnancy, data on TTP were available for 
721 and 787 pregnancies from 378 CCSs and 369 controls, 
respectively. Overall TTP did not appear significantly longer 
in CCSs compared to controls [1.1 times longer (p = 0.09)]. 
However, in survivors of CNS and renal tumours TTP was 
significantly longer (Table 2), in renal tumours particularly 
following treatment with lower abdominal/pelvic radio-
therapy (ratio 1.5, 95%CI 1.0–2.2). For CNS survivors, no 
particular treatment factor was associated with a longer TTP 
(data not shown). None of the CED-score categories, nor 
any of the individual alkylating agents (yes/no) was signifi-
cantly associated with TTP (data not shown). Only lower 
abdominal/pelvic radiotherapy was borderline significantly 
associated with a longer TTP (p = 0.08).
TTP analyzed for first, second, and third pregnancies sep-
arately did not differ significantly between CCSs and con-
trols nor did TTP for pregnancies by spontaneous conception 
and by conception using assisted reproductive techniques 
(Supplementary Table 2).
Obstetric outcomes
Among all women who participated in the study, 415 survi-
vors and 401 controls reported a total of 845 and 890 preg-
nancies, respectively. Data on outcomes of 786 (93%) and 
853 (96%) pregnancies among 392 survivors and 387 con-
trols, respectively, were available for analyses. Overall, no 
differences were found between CCSs and controls regarding 
the probability of experiencing a still birth, miscarriage, or 
induced abortion (OR 2.0, 95%CI 0.5–7.6; OR 1.2, 95%CI 
0.8–1.6; OR 0.7, 95%CI 0.5–1.2, respectively) (Table 3). 
However, a significantly increased probability of miscarriage 
was found specifically among survivors of leukemia (OR 
1.6, 95%CI 1.1–2.3) which seemed to be related to treat-
ment with TBI, administered as part of conditioning regimen 
for SCT, although numbers were too small to perform valid 
statistical tests. Of the 11 pregnancies among leukaemia 
survivors who received TBI, eight (73%) ended in a mis-
carriage and one (9%) in a still birth. For the renal tumour 
survivor group as a whole the probability of miscarriage 
was also increased, reaching borderline significance (OR 
1.9, 95%CI 1.0–3.5). Additional analysis showed particu-
larly renal tumour survivors treated with lower abdominal/
pelvic radiotherapy to be at increased risk (OR 2.4, 95%CI 
1.1–5.1). In addition, women who received a SCT had a 
significantly increased risk of a miscarriage (OR 8.2, 95%CI 
2.2–30.0). None of the investigated diagnosis- or treatment-
related factors appeared to be associated with in an increased 
risk of induced abortion.
Overall, 57 (10%) and 31 (5%) live births from CCSs 
and controls, respectively, were delivered preterm (OR 
2.0, 95%CI 1.2–3.5) (Table 4). This risk was significantly 
higher specifically among survivors of renal tumours, bone 
tumours, and soft tissue sarcomas. The risk of a preterm 
delivery among renal tumour survivors was independent of 
having received lower abdominal/pelvic radiotherapy (data 
not shown). For survivors of bone tumours and soft tissue 
sarcomas, the numbers were too small to further investi-
gate which type of treatment primarily contributed to a 
preterm delivery. Moreover, CCSs diagnosed before the 
age of 10 years had a significantly higher probability of a 
preterm delivery, which seemed to be related to treatment 
with treatment with lower abdominal/pelvic radiotherapy. 
Overall, treatment with lower abdominal/pelvic radio-
therapy or cranial/spinal radiotherapy, but also with CED-
score > 4000–8000, resulted in a higher risk of a preterm 
delivery.
No significant differences were found regarding the risk 
of SGA offspring among CCSs (11%) compared to controls 
Table 1  (continued) Values represent the number (%) of women, unless indicated otherwise. The subcategories may not add up 
to the total number of women due to missing values
BMI body mass index, CED cyclophosphamide equivalent dose, CNS central nervous system, RT radio-
therapy, TBI total body irradiation
a Categorized as low: up to and including lower technical and vocational training; medium: up to and 
including secondary technical and vocational training; high: up to and including higher technical and voca-
tional training and university
b Corrected for age at time of study
c Other diagnoses include thyroid carcinomas (n = 6), retinoblastomas (n = 3), hepatoblastomas (n = 3), 
nasopharyngeal carcinomas (n = 3), other (n = 3)
d Cyclophosphamide equivalent dose (CED) score (Green et al. 2014)
e Includes cranial, spinal, and craniospinal RT. 14/232 (6%) patients treated with cranial/spinal RT also 
received other RT
f 4/88 (5%) patients treated with lower abdominal/pelvic RT also received cranial/spinal RT and 12/88 
(14%) patients also received other RT
g 3/33 (9%) patients treated with TBI also received cranial/spinal RT
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Table 2  Diagnosis- and 
treatment-related factors 
associated with time to 
pregnancy according to 
five different models: (1) 
type of diagnosis; (2) age at 
diagnosis; (3) CED score; (4) 
radiotherapy site; (5) stem cell 
transplantation
CED cyclophosphamide equivalent dose, CNS central nervous system, RT radiotherapy, TBI total body 
irradiation
a Corrected for age at time of pregnancy and educational level
b Corrected for age at time of pregnancy, educational level, and gonadotoxic radiotherapy (i.e. lower 
abdominal/pelvic RT and/or TBI) (yes or no)
c Corrected for age at time of pregnancy, educational level and alkylating agent therapy (yes or no)
Total number of 
pregnancies
Time to pregnancy (months); 
Median (IQR)
Ratio (95% CI)
Controls 787 3.0 (1.0–7.5) Ref.
Survivors 721 3.0 (1.0–8.0) 1.1 (1.0–1.2)a
Model 1: type of diagnosisa
Controls 787 3.0 (1.0–7.5) Ref.
Leukaemia 236 3.0 (1.0–7.3) 1.1 (0.9–1.2)
Lymphoma 164 3.0 (1.0–8.0) 1.1 (0.9–1.4)
CNS tumours 27 7.0 (3.0–12.0) 2.0 (1.3–3.0)
Neuroblastoma and other peripheral 
nervous cell tumours
60 3.5 (1.3–9.0) 1.0 (0.8–1.3)
Renal tumours 66 3.5 (1.4–12.0) 1.3 (1.0–1.8)
Bone tumours 72 3.0 (2.0–5.8) 1.0 (0.8–1.3)
Soft tissue sarcoma 49 3.0 (1.8–6.0) 0.9 (0.7–1.2)
Germ cell tumours 24 2.0 (1.0–3.8) 0.9 (0.5–1.5)
Other 23 4.0 (2.0–9.0) 1.3 (0.8–1.9)
Model 2: age at diagnosis (years)a
Controls 787 3.0 (1.0–7.5) Ref.
< 10 408 3.0 (1.5–9.0) 1.1 (1.0–1.3)
≥ 10 to < 13 120 3.0 (1.0–8.8) 1.1 (0.9–1.4)
≥ 13 193 3.0 (1.0–7.5) 1.1 (0.9–1.3)
Model 3: CED scoreb
Controls 787 3.0 (1.0–7.5) Ref.
0 354 3.0 (1.0–9.0) 1.1 (0.9–1.2)
> 0 to ≤ 4000 mg/m2 100 3.0 (1.0–7.0) 1.0 (0.8–1.3)
> 4000 to ≤ 8000 mg/m2 104 4.0 (1.3–8.0) 1.1 (0.9–1.4)
> 8000 mg/m2 142 3.0 (2.0–8.0) 1.1 (0.9–1.4)
Model 4: radiotherapy body sitec
Controls 787 3.0 (1.0–7.5) Ref.
No RT 377 3.0 (1.0–7.0) 1.0 (0.9–1.2)
Cranial/spinal RT 161 4.0 (1.0–9.0) 1.2 (0.9–1.5)
 Low dose (< 20 Gy) 47 3.0 (1.0–7.0) 1.2 (0.7–2.0)
 Medium dose (20–30 Gy) 73 4.0 (2.0–12.0) 1.3 (0.9–1.8)
 High dose (≥ 30 Gy) 38 6.0 (1.0–9.8) 1.3 (0.8–2.1)
Lower abdominal/pelvic RT 64 4.8 (2.0–10.5) 1.3 (1.0–1.8)
 Low dose (< 20 Gy) 26 6.5 (2.0–14.5) 1.7 (0.9–2.9)
 Medium dose (20–30 Gy) 15 3.0 (0.0–6.0) 1.0 (0.6–1.9)
 High dose (≥ 30 Gy) 23 5.0 (3.0–12.0) 1.5 (1.0–2.4)
TBI 7 5.0 (4.0–10.0) 1.2 (0.5–2.7)
Other RT 104 3.0 (2.0–6.0) 1.0 (0.8–1.3)
Model 5: stem cell transplantationa
Controls 787 3.0 (1.0–7.5) Ref.
No 696 3.0 (1.0–8.0) 1.1 (1.0–1.2)
Yes 14 4.8 (0.8–10.5) 1.2 (0.6–2.3)
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Table 3  Diagnosis- and treatment-related factors associated with miscarriage, induced abortion and still birth, according to five different models: 
(1) type of diagnosis; (2) age at diagnosis; (3) CED score; (4) radiotherapy site; (5) stem cell transplantation
Values represent the number (%) of women, unless indicated otherwise. The subcategories may not add up to the total number of women due to 
missing values
CED cyclophosphamide equivalent dose, CNS central nervous system, RT radiotherapy, TBI total body irradiation
a Corrected for age at time of pregnancy and educational level
b Corrected for age at time of pregnancy, educational level, and gonadotoxic radiotherapy (i.e. lower abdominal/pelvic RT and/or TBI) (yes or no)
c Corrected for age at time of pregnancy, educational level, and alkylating agent therapy (yes or no)
Total number 
of pregnancies
Pregnancy outcome
Live birth Miscarriage Induced abortion Still birth Miscarriage OR (95% CI) Induced abor-
tion OR (95% 
CI)
Controls 853 651 (76.3) 138 (16.2) 60 (7.0) 4 (0.5) Ref. Ref.
Survivors 786 592 (75.3) 138 (17.6) 48 (6.1) 8 (1.0) 1.2 (0.8–1.6)a 0.7 (0.5–1.2)a
Model 1: Type of diagnosisa
Controls 853 651 (76.3) 138 (16.2) 60 (7.0) 4 (0.5) Ref. Ref.
Leukaemia 269 191 (71.0) 57 (21.2) 18 (6.7) 3 (1.1) 1.6 (1.1–2.3) 1.0 (0.5–2.0)
Lymphoma 166 134 (80.7) 19 (11.4) 12 (7.2) 1 (0.6) 0.8 (0.4–1.3) 0.6 (0.2–1.5)
CNS tumours 33 25 (75.8) 6 (18.2) 2 (6.1) 0 1.3 (0.5–3.4) –
Neuroblastoma and other 
peripheral nervous cell 
tumours
56 45 (80.4) 7 (12.5) 1 (1.8) 3 (5.4) 0.7 (0.3–2.1) –
Renal tumours 72 53 (73.6) 17 (23.6) 2 (2.8) 0 1.9 (1.0–3.5) –
Bone tumours 76 61 (80.3) 10 (13.2) 4 (5.3) 1 (1.3) 0.5 (0.2–1.6) –
Soft tissue sarcoma 55 43 (78.2) 9 (16.4) 3 (5.5) 0 1.2 (0.6–2.5) –
Germ cell tumours 31 21 (67.7) 8 (25.8) 2 (6.5) 0 1.5 (0.5–4.4) –
Other 28 19 (67.9) 5 (17.9) 4 (14.3) 0 0.6 (0.2–2.0) –
Model 2: Age at diagnosis (years)a
Controls 853 651 (76.3) 138 (16.2) 60 (7.0) 4 (0.5) Ref. Ref.
< 10 442 332 (75.1) 75 (17.0) 30 (6.8) 5 (1.1) 1.1 (0.8–1.6) 0.8 (0.5–1.5)
≥ 10 to < 13 139 105 (75.5) 23 (16.5) 8 (5.8) 3 (2.2) 1.2 (0.7–2.0) 0.7 (0.3–1.8)
≥ 13 205 155 (75.6) 40 (19.5) 10 (4.9) 0 1.2 (0.8–1.9) 0.5 (0.2–1.4)
Model 3: CED scoreb
Controls 853 651 (76.3) 138 (16.2) 60 (7.0) 4 (0.5) Ref. Ref.
0 394 301 (76.4) 68 (17.3) 23 (5.8) 2 (0.5) 1.1 (0.8–1.6) 0.9 (0.5–1.7)
> 0 to ≤ 4000 mg/m2 121 78 (64.5) 33 (27.3) 9 (7.4) 1 (0.8) 1.4 (0.8–2.5) 0.6 (0.2–1.9)
> 4000 to ≤ 8000 mg/m2 102 82 (80.4) 11 (10.8) 6 (5.9) 3 (2.9) 0.5 (0.2–1.3) 1.0 (0.4–2.5)
> 8000 mg/m2 146 114 (78.1) 21 (14.4) 9 (6.2) 2 (1.4) 0.8 (0.5–1.4) 0.7 (0.2–2.0)
Model 4: Radiotherapy body sitec chi
Controls 853 651 (76.3) 138 (16.2) 60 (7.0) 4 (0.5) Ref. Ref.
No RT 400 305 (76.3) 61 (15.3) 30 (7.5) 4 (1.0) 1.1 (0.7–1.7) 0.9 (0.5–1.9)
Cranial/spinal RT 183 141 (77.0) 35 (19.1) 5 (2.7) 2 (1.1) 1.3 (0.8–2.2) 0.8 (0.3–2.1)
Lower abdominal/pelvic 
RT
72 54 (75.0) 17 (23.6) 1 (1.4) 0 1.8 (0.9–3.5) –
TBI 11 2 (18.2) 8 (72.7) 0 1 (9.1) – –
Other RT 113 86 (76.1) 15 (13.3) 11 (9.7) 1 (0.9) 1.1 (0.6–2.1) 1.1 (0.4–3.1)
Model 5: Stem cell transplantationa
Controls 853 651 (76.3) 138 (16.2) 60 (7.0) 4 (0.5) Ref. Ref.
No 756 577 (76.3) 125 (16.5) 47 (6.2) 7 (0.9) 1.1 (0.8–1.4) 0.7 (0.4–1.2)
Yes 16 6 (37.5) 9 (56.3) 0 1 (6.3) 8.2 (2.2–30.0) –
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Table 4  Diagnosis- and treatment-related factors associated with obstetric outcomes according to five different models: (1) type of diagnosis; (2) 
age at diagnosis; (3) CED score; (4) radiotherapy site; (5) stem cell transplantation
Values represent the number (%) of women, unless indicated otherwise. The subcategories may not add up to the total number of women due to 
missing values
CED cyclophosphamide equivalent dose, CNS central nervous system, RT radiotherapy, SGA small for gestational age, TBI total body irradiation
a Percentage of the live births for whom the gestational week was known
b Percentage of the live births for whom SGA could be calculated
c Percentage of the live births for whom the method of delivery was known
d Corrected for age at time of pregnancy and educational level
e Corrected for age at time of pregnancy, educational level, and gonadotoxic radiotherapy (i.e. lower abdominal/pelvic RT and/or TBI) (yes or no)
f Corrected for age at time of pregnancy, educational level, and alkylating agent therapy (yes or no)
Total number 
of live births
Preterm delivery SGA Caesarean section
N (%)a OR (95% CI) N (%)b OR (95% CI) N (%)c OR (95% CI)
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
Survivors 592 57 (9.8) 2.0 (1.2–3.5)d 59 (10.7) 1.1 (0.7–1.7)d 108 (19.2) 1.8 (1.2–2.6)d
Model 1: Type of diagnosisd
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
Leukaemia 191 13 (7.0) 1.4 (0.6–2.9) 16 (9.0) 0.8 (0.4–1.5) 35 (19.3) 1.8 (1.1–3.0)
Lymphoma 134 12 (9.2) 1.7 (0.7–3.7) 11 (8.7) 0.8 (0.4–1.7) 16 (12.6) 0.9 (0.5–1.9)
CNS tumours 25 4 (16.0) – 4 (17.4) – 6 (24.0) 2.2 (0.7–4.6)
Neuroblastoma and other peripheral 
nervous cell tumours
45 2 (4.4) – 8 (19.0) 2.4 (1.1–5.3) 8 (18.6) 1.9 (0.8–4.6)
Renal tumours 53 10 (18.9) 4.9 (2.1–11.6) 3 (6.0) – 12 (24.0) 2.7 (1.2–6.1)
Bone tumours 61 7 (11.9) 2.8 (1.1–7.0) 8 (14.0) 1.7 (0.7–4.0) 14 (24.1) 2.3 (1.1–5.1)
Soft tissue sarcoma 43 7 (16.3) 4.0 (1.3–12.6) 7 (17.5) 2.0 (0.7–5.8) 13 (31.7) 3.4 (1.4–8.4)
Germ cell tumours 21 1 (4.8) – 1 (4.8) – 2 (9.5) –
Other 19 1 (5.3) – 1 (5.3) – 2 (10.5) –
Model 2: Age at diagnosis (years)d
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
< 10 332 38 (11.7) 2.5 (1.4–4.4) 31 (10.0) 1.0 (0.6–1.6) 68 (21.4) 2.1 (1.4–3.2)
≥ 10 to< 13 105 9 (8.7) 1.9 (0.8–4.5) 12 (12.0) 1.2 (0.6–2.6) 15 (15.3) 1.4 (0.7–2.9)
≥ 13 155 10 (6.7) 1.3 (0.5–3.4) 16 (11.5) 1.2 (0.6–2.5) 25 (17.1) 1.4 (0.8–2.6)
Model 3: CED scoree
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
0 301 28 (9.6) 1.9 (1.0–3.6) 23 (8.3) 0.8 (0.5–1.4) 57 (19.5) 2.0 (1.2–3.1)
> 0 to ≤ 4000 mg/m2 78 6 (7.7) 1.1 (0.4–3.1) 11 (15.1) 1.5 (0.6–3.9) 15 (21.4) 2.1 (1.0–4.4)
> 4000 to ≤ 8000 mg/m2 82 12 (14.8) 3.0 (1.3–7.4) 9 (11.4) 1.2 (0.5–2.6) 24 (30.0) 2.9 (1.5–5.6)
> 8000 mg/m2 114 10 (8.8) 1.6 (0.7–3.6) 14 (13.0) 1.4 (0.7–2.8) 12 (11.5) 0.8 (0.4–1.8)
Model 4: Radiotherapy body sitef
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
No RT 305 28 (9.4) 2.1 (1.0–4.3) 19 (6.6) 0.5 (0.3–1.0) 45 (15.8) 1.6 (0.9–2.7)
Cranial/spinal RT 141 14 (10.1) 2.1 (1.0–4.5) 19 (15.0) 1.2 (0.6–2.3) 36 (26.1) 2.8 (1.5–5.0)
Lower abdominal/pelvic RT 54 8 (14.8) 4.0 (1.6–10.1) 4 (8.3) – 11 (21.2) 2.1 (0.9–5.2)
TBI 2 1 (50.0) – 1 (50.0) – 0 –
Other RT 86 6 (7.2) 1.6 (0.6–4.6) 15 (18.8) 1.5 (0.6–3.7) 15 (18.3) 1.9 (0.9–4.2)
Model 5: Stem cell transplantation
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
No 577 56 (9.9) 2.1 (1.2–3.6) 57 (10.6) 1.1 (0.7–1.7) 106 (19.3) 1.8 (1.2–2.6)
Yes 6 0 – 0 – 1 (16.7) –
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(10%), with the exception of neuroblastoma survivors (OR 
2.4, 95%CI 1.1–5.3) in whom no specific type of treatment 
associated with this finding could be identified.
Furthermore, 108 (19%) and 77 (12%) of live births in 
CCSs and controls, respectively, were delivered via caesar-
ean section (OR 1.8, 95%CI 1.2–2.6). Survivors of leukae-
mia, renal tumours, bone tumours, and soft tissue sarcoma 
were at a significantly increased risk of a caesarean sec-
tion (Table 4). Within the group of leukaemia survivors, 
treatment with cranial/spinal radiotherapy was significantly 
associated with ever having had a caesarean section (OR 
3.0, 95%CI 1.4–6.1), while lower abdominal/pelvic radio-
therapy appeared to be the main associated factor within the 
group of renal tumour survivors (OR 2.7, 95%CI 1.0–7.4). 
All soft tissue sarcoma survivors who received cranial/spi-
nal radiotherapy delivered via caesarean section, whereas 
for bone tumour survivors no specific types of chemo- or 
radiotherapy were associated with delivering via caesarean 
section. Moreover, survivors diagnosed before the age of 
10 years were significantly more likely to have delivered via 
a caesarean section, which was related to treatment with cra-
nial/spinal radiotherapy. Moreover, overall analyses showed 
that treatment with cranial/spinal radiotherapy resulted in a 
significantly higher probability of delivering via caesarean 
section (OR 2.8, 95%CI 1.5–5.0).
Discussion
This is the first study which assessed pregnancy rates among 
female CCSs and controls who ever pursued pregnancy. 
Moreover, this is one of the first studies assessing specific 
diagnosis- and treatment-related factors associated with 
pregnancy rates, TTP and adverse obstetric outcomes using 
a large, nationwide, cohort of female CCSs.
Our results show that the chance of becoming pregnant 
was significantly lower for CCSs compared to controls, 
which is in line with previous studies (Green et al. 2009b; 
Chow et al. 2016; Armuand et al. 2017). In most of these 
studies results regarding pregnancy rates were adjusted for 
marital status, as an alternative way to correct for the fact 
that not all study participants did actually want to become 
pregnant. These studies appeared to provide similar results 
as our study, which is reassuring in terms of the robustness 
of our findings. However, the fact that our analyses were 
performed among the subgroup of participants who ever pur-
sued pregnancy, has yielded more valid estimates regarding 
the actual chance of becoming pregnant following childhood 
cancer. Similar to Green et al., high dose cranial radiother-
apy (> 30 Gy) and medium and high dose abdominal/pelvic 
radiotherapy were found as risk factors for reduced preg-
nancy rates in addition to TBI or SCT. Conditioning treat-
ment for SCT often includes chemotherapeutic agents such 
as busulfan, lomustine or cyclophosphamide, all of which 
have been associated with reduced pregnancy rates (Green 
et al. 2009b; Chow et al. 2016). Due to the limited numbers 
of patients who received these alkylating agents in our study, 
we were unable to identify this association.
Overall, no difference in TTP between CCSs and controls 
was found. This contrasts to Barton et al. who reported a 
significantly increased TTP for CCSs (Barton et al. 2013). 
However, as opposed to this study, we included all pregnan-
cies and corrected our analyses for maternal age at preg-
nancy and maternal educational level at time of study, both 
factors known to be associated with TTP (Mutsaerts et al. 
2012). Our results may indicate that CCSs are more aware 
of the possible impact of their former treatment on repro-
ductive function, as a result of improved and more frequent 
counseling. Therefore, they may start attempting to become 
pregnant at a younger age, thereby counteracting the adverse 
impact of treatment on TTP. This seems to be substantiated 
by our finding that CCSs were younger than controls at the 
time of their first pregnancy. After adjustment for educa-
tional level, a trend towards a younger age at first pregnancy 
among CCSs was still observed. Moreover, TTP was inves-
tigated not only for first pregnancies but for all pregnan-
cies. Our results revealed no differences in TTP between 
CCSs and controls for any of the subsequent pregnancies. 
These findings suggest that although ovarian reserve may 
be decreased in female CCSs (van den Berg et al. 2018), 
the quality of the oocytes in the remaining follicle pool is 
not compromised (Somigliana et al. 2018) as opposed to 
ageing women where both the quantity and quality of the 
remaining follicles are reduced (Bruin et al. 2004; Wallace 
and Kelsey 2010).
Survivors of CNS and renal tumours had a significantly 
longer TTP compared to controls, particularly after lower 
abdominal/pelvic radiotherapy in renal tumour survivors 
which may have resulted in a decreased ovarian reserve or a 
damaged uterus not facilitating conception and/or implanta-
tion (Green et al. 2009a; van den Berg et al. 2018; Teh et al. 
2014). For CNS-tumour survivors, none of the radiotherapy 
body sites significantly contributed to a longer TTP suggest-
ing that having had a CNS tumour, rather than treatment 
with radiotherapy is associated with longer TTP. It should 
however be noted that the number of pregnancies within 
these subgroups was low. Brinkman et al. reported that sur-
vivors of childhood CNS tumours, treated with and without 
cranial radiotherapy, are at an increased risk of neurocogni-
tive impairment (Brinkman et al. 2016). As a consequence, 
they may have fertility-related knowledge deficits and incor-
rect perceptions regarding their reproductive window lead-
ing to more problems when trying to conceive (Hammarberg 
et al. 2013). However, TTP was less than 12 months for the 
majority of the CNS (78%) and renal tumor survivors (79%), 
indicating that clinically they are not considered subfertile 
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(Practice Committee of American Society for Reproductive 
M 2008).
It has been suggested previously that cranial irradiation 
increases the risk of miscarriage, possibly through impair-
ment of the hypothalamic-pituitary-ovarian-axis function 
(Green et al. 2002; Bath et al. 2001). However, this was 
not confirmed in our study, nor in the study by Reulen 
et al. (2009). Further research is needed to investigate the 
exact effect of cranial radiotherapy and associated pituitary 
hormone deficits on the risk of miscarriages. In addition, 
although we found SCT to be associated with an increased 
risk of miscarriage, numbers were too small to further inves-
tigate which factor primarily contributed to this increased 
risk, i.e. TBI or other aspects of SCT. However, as in another 
study (Sanders et al., 1996), our results suggest a role for 
TBI since 8/11 (73%) pregnancies of survivors treated with 
TBI as part of a SCT resulted in a miscarriage, whereas 
only 1/6 pregnancies (17%) of survivors not treated with TBI 
prior to SCT resulted in a miscarriage.
In line with previous studies, survivors were at 
increased risk of a preterm delivery in general (Madanat-
Harjuoja et al. 2010; Mueller et al. 2009) and in particular 
survivors who received lower abdominal/pelvic radiother-
apy (Reulen et al. 2009; 2017; Lie Fong et al. 2010; Green 
et al. 2010). Radiotherapy to the uterus during childhood 
has previously been associated with damage to the uterus 
vasculature, its elasticity, and volume (Larsen et al. 2003; 
Wo and Viswanathan 2009; Loo et al. 2019), restricting 
a survivors ability to carry the fetus to term. However, 
since in our study the risk of preterm delivery appeared 
independent of having received lower abdominal/pelvic 
radiotherapy, other factors than cancer treatment may 
also contribute, such as hypertension or diabetes melli-
tus (as a result of either the pregnancy itself or previous 
cancer treatment). In our population 27% (14/52) of the 
survivors who ever delivered prematurely, also suffered 
from hypertension during pregnancy, while this propor-
tion was 12% (3/25) among controls. No diabetes during 
pregnancy was reported. In addition, a significantly higher 
risk of a preterm delivery was found in CCSs treated with 
lower abdominal/pelvic radiotherapy before the age of 
10 years. This is in line with previous studies indicating 
that radiotherapy to the uterus administered pre-pubertally 
is associated with a smaller uterus in adulthood, as uterine 
development is not completed before the onset of puberty 
(Bath et al. 1999; Bruin et al. 2009), thereby increasing 
the risk of delivering preterm. Finally, we found soft tis-
sue sarcoma survivors to be at increased risk of preterm 
delivery. Although actual numbers withheld us from per-
forming additional analyses into the specific type of treat-
ment responsible for this increased risk, the location of the 
tumour seems critical: among survivors whose sarcoma 
was located in the uterus, four of the five pregnancies 
(80%) resulted in a preterm delivery, whereas this pro-
portion was 8% (3/38 pregnancies) among those whose 
primary sarcoma originated from non-uterine soft tissues.
Our study showed that survivors had a higher risk of 
delivering via caesarean section compared to controls, 
which is in line with previous studies. (Reulen et al. 2017; 
van der Kooi et al. 2018; Melin et al. 2015). Possibly a 
history of cancer may lead to increased surveillance and 
a lower threshold for interventions, such as caesarean 
sections.
Strengths of the current study, besides the fact that it is 
the first study evaluating TTP in all pregnancies, include 
the evaluation of the chance of becoming pregnant among 
the group that actually pursued pregnancy, the inclusion 
of a large control group, and the availability of detailed 
cancer treatment information. Moreover, we evaluated the 
risk of each adverse pregnancy outcome relative to a live 
birth, while previous studies evaluated each adverse preg-
nancy outcome relative to all other pregnancy outcomes, 
thereby underestimating the actual risks.
Our study also has some limitations. First, our study 
may have been subject to participation bias, since par-
ticipating CCSs may differ from non-participating CCSs. 
However, participating and non-participating CCSs did not 
differ regarding age at study, age at diagnosis, and type 
of diagnosis (Supplementary Table 3). The proportion of 
CCSs treated with chemotherapy only was significantly 
higher among participants compared to non-participants. 
This may indicate that the more heavily treated CCSs did 
not participate, which would imply that the reported risks 
of adverse obstetric outcomes may be an underestimation 
of the actual risk. Furthermore, although it is known that 
TTP and obstetric outcomes are associated with factors 
such as BMI, smoking behavior, and menstrual cycle 
length, our analyses were not corrected for these factors, 
since for these factors only data at time of study were 
available and not at time of pregnancy, which may have 
occurred years earlier. Finally, women who tried but failed 
to conceive were not included in the analyses regarding 
TTP. Consequently, our findings on TTP are valid for 
CCSs who have proven to be fertile only.
In conclusion, although the chance of becoming pregnant 
is significantly lower for CCSs compared to controls, it is 
reassuring that overall, CCSs who become pregnant are not 
at increased risk of a longer TTP, stillbirth, miscarriage, or 
induced abortion. Nevertheless, the risk of delivering pre-
term or via caesarean section is higher among CCSs com-
pared to controls and specific subgroups of CCSs seem to be 
at increased risk of longer TTP and several adverse obstetric 
outcomes, especially those who received lower abdominal/
pelvic irradiation. Close obstetric monitoring for these sur-
vivors is of high importance. Moreover, our results can be 
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incorporated in clinical guidelines regarding obstetric care 
in female CCSs.
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